Cambridge Healthtech Institute’s Third Annual 

Predictive Preclinical Models in Oncology 

Mastering Translational Oncology with Predictive Models and Novel In-Silico Approaches

March 7-9, 2016 | Moscone North Convention Center | San Francisco, CA
Part of the 23rd International Molecular Medicine Tri-Conference


Despite tremendous progress in our understanding of cancer biology, the majority of novel anticancer therapies fail in clinical trials, which indicates failure of conventional translational approaches. A major challenge in the development of novel anticancer agents is the design and interpretation of first-in-man trials. The key study design elements such as schedule, escalation strategy, targeted patient population, etc. rely heavily on preclinical (usually in vivo) data. This situation brings into question the predictability of preclinical tumor models as well as the method to analyze and translate the results of preclinical studies. In that regard, better in vivo models, coupled with careful translational PK/PD modeling hold the potential to significantly increase the value of preclinical results. Better predictive modeling would hopefully permit more effective evaluation of novel cancer therapeutics, (for example, cancer immunotherapeutics), as well as the more rational design of potent anticancer drug combinations. Cambridge Healthtech Institute’s Fourth Annual Predictive Pre-Clinical Models in Oncology is designed to highlight cutting edge advances in in vivo, in vitro and in silico modeling and to facilitate a discussion about effective translational approaches in cancer research.

Preliminary Agenda


Utilizing Large-Scale in vivo Screening with PTX Models Predicts Drug Response in Cancer Patients

Juliet Williams, Ph.D., Head, Oncology Drug Discovery, Novartis Institute for Biomedical Research

Reverse Translation: What Clinical Oncology Can Teach Preclinical Oncology

Pamela N. Munster, M.D., Professor, Medicine, Program Leader Development Therapeutics, Director, Early Phase Clinical Trials' Program, Helen Diller Cancer Center, University of California, San Francisco Statistical

Analysis of PDX Studies and Preclinical Phase-II-Like Trials (PP2T) at EMD Serono
Anderson Clark, Ph.D., Director, In vivo Pharmacology, Oncology, EMD Serono Research & Development

Optimizing Clinical Trial Designs by PDX Integration

Joint Presentation:
David Gandara, M.D., Professor, Medicine, Division of Hematology/Oncology, University of California, Davis School of Medicine; Director, Thoracic Oncology Program, Senior Advisor to the Director, University of California, Davis Comprehensive Cancer Center; Chair, Lung Committee, Southwest Oncology Group (SWOG)
Philip C. Mack, Ph.D., Associate Adjunct Professor, Internal Medicine, Hematology and Oncology, University of California, Davis Medical Center
Mary Redman, Ph.D., Lead Statistician, Lung Cancer Committee Southwest Oncology Group, Lead Statistician, Lung Map Trial, Fred Hutchinson Cancer Research Center

Co-Clinical Trials of Targeted Therapies in Colorectal Cancer Patients and Patient-Derived Xenografts

Joint Presentation: Chloe E. Atreya M.D., Ph.D., Assistant Clinical Professor, Gastrointestinal Oncology Program, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center
Byron C. Hann, M.D., Ph.D., Associate Researcher, Manager of Preclinical Therapeutics Core, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center

Champions OncologyAdvanced PDX Tumor Biology Platforms for Drug Advancement

Neal Goodwin, Vice President, Corporate Research & Development, Champions Oncology


The Mechanistic Basis of Cancer Immunotherapy

Ira Mellman, M.D., Vice President, Cancer Immunology, Genentech

Preclinical Tumor Models for Evaluating Bispecific Redirected T-Cell Therapeutics

Chad May, Ph.D., Director, Oncology Research Unit, Pfizer

Mechanistic Basis of Palbociclib Resistance and Combinatorial Activity in ER+ Breast Non-Breast Cancer Indications

Stephen Dann, PH.D., Principal Scientist, Pfizer Oncology Research Unit

Improved Systemic Responses through the Rational Combination of Immunotherapy with Radiation

James W. Welsh, M.D., Associate Professor, Division of Radiation Oncology, The University of Texas MD Anderson Cancer Center

Assessing ENPP3 as a Renal Cancer Target for Bi-Specific T-Cell Engager (BiTE®) Therapy

Olivier Nolan-Stevaux, Ph.D., Senior Scientist, Oncology Research, Amgen, Inc.

Jackson LaboratoryPatient-derived Tumor Xenografts in Humanized NSG-SGM3 Mice: a New Immuno-oncology Platform

James G. Keck, Ph.D., Senior Director, Clinical Lab & In Vivo Pharmacology Services, The Jackson Laboratory


Markers, Mechanisms and Treatment of Resistant Cancer

Bruce R. Zetter, Ph.D. Charles Nowiszewski Professor, Cancer Biology, Surgery, Harvard Medical School

Tackling Cancer Drug Resistance in Brain Tumors

Eric C. Holland, M.D., Ph.D., Senior Vice President, Director, Human Biology, Solid Tumor Translational Research, Nancy and Buster Alvord Brain Tumor Center, Fred Hutchinson Cancer Research Center, University of Washington

Premier Sponsors:  

Bina Technologies




Jackson Laboratory - small logo 


 Precision for Medicine 


Silicon Biosystems

Thomson Reuters-Large